D.A. Davidson & CO. Raises Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

D.A. Davidson & CO. increased its position in iShares Biotechnology ETF (NASDAQ:IBB) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,778 shares of the financial services provider’s stock after acquiring an additional 118 shares during the period. D.A. Davidson & CO.’s holdings in iShares Biotechnology ETF were worth $500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC raised its stake in shares of iShares Biotechnology ETF by 2.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock valued at $510,000 after buying an additional 94 shares during the last quarter. Capital Investment Advisors LLC raised its stake in shares of iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock valued at $1,381,000 after buying an additional 99 shares during the last quarter. Magnus Financial Group LLC raised its stake in shares of iShares Biotechnology ETF by 0.8% during the 4th quarter. Magnus Financial Group LLC now owns 12,967 shares of the financial services provider’s stock valued at $1,714,000 after buying an additional 104 shares during the last quarter. Burke & Herbert Bank & Trust Co. raised its stake in shares of iShares Biotechnology ETF by 1.2% during the 4th quarter. Burke & Herbert Bank & Trust Co. now owns 8,809 shares of the financial services provider’s stock valued at $1,165,000 after buying an additional 105 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of iShares Biotechnology ETF by 12.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 1,028 shares of the financial services provider’s stock valued at $150,000 after buying an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 0.6 %

NASDAQ IBB opened at $137.86 on Wednesday. The stock has a 50-day simple moving average of $135.64 and a two-hundred day simple moving average of $140.74. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.